DEATHS IN PATIENTS RECEIVING ORAL IRON CHELATOR L1
نویسندگان
چکیده
منابع مشابه
Oral iron chelator L1 and autoimmunity.
As Brittenham’ has reviewed in detail, the use of the oral iron chelator LI has been associated with significant clinical and animal toxicity. One of the more controversial issues surrounding the human use of LI has been the possible development of autoimmune phenomena as manifested by development of autoantibodies such as antinuclear antibodies (ANA). The Canadian group investigating LI did no...
متن کاملImmunological evaluation of β-thalassemia major patients receiving oral iron chelator deferasirox.
OBJECTIVE To determine the immune abnormalities and occurrence of infections in transfusion-dependent β-thalassemia major patients receiving oral iron chelator deferasirox (DFX). STUDY DESIGN An observational study. PLACE AND DURATION OF STUDY Hematology Clinics, King Khalid University Hospital, Riyadh, Saudi Arabia, from July to December 2010. METHODOLOGY Seventeen patients with β-thalas...
متن کاملZinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine.
AIMS To determine the changes in serum zinc concentration and the extent of urinary zinc excretion in patients with iron overload receiving the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) or desferrioxamine (DFX), and to correlate these results with blood glucose concentration. METHODS Serum zinc and ferritin concentrations, urinary zinc and iron excretion were regularly assayed...
متن کاملIron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease.
Several life-threatening complications of the common disorder sickle cell disease require management with red blood cell transfusions and, hence, long-term iron-chelating therapy. The efficacy of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) has not previously been determined in patients with sickle cell disease. We compared the efficacy of L1 to that of standard-dose subcutaneo...
متن کاملChelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1).
BACKGROUND AND OBJECTIVE Excessive hemosiderosis is the main reason for the multi-organ failure observed in multitransfused patients. Deferiprone (1,2-dimethyl-3-hydroxy-pyridine-4-one, L1) is an orally active iron chelator mainly excreted via urine. We conducted a study in order to determine the efficacy and safety of L1 in Greek thalassemic patients. DESIGN AND METHODS A group of 11 thalass...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Haematology
سال: 1993
ISSN: 0007-1048,1365-2141
DOI: 10.1111/j.1365-2141.1993.tb03196.x